Literature DB >> 21277939

Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Partha Mukhopadhyay1, Subhankar Chakraborty, Moorthy P Ponnusamy, Imayavaramban Lakshmanan, Maneesh Jain, Surinder K Batra.   

Abstract

Mucins are high molecular weight, multifunctional glycoproteins comprised of two structural classes-the large transmembrane mucins and the gel-forming or secreted mucins. The primary function of mucins is to protect and lubricate the luminal surfaces of epithelium-lined ducts in the human body. Recent studies have identified a differential expression of both membrane bound (MUC1, MUC4 and MUC16) and secreted mucins (MUC2, MUC5AC, MUC5B and MUC6) in breast cancer tissues when compared with the non-neoplastic breast tissues. Functional studies have also uncovered many unique roles of mucins during the progression of breast cancer, which include modulation in proliferative, invasive and metastatic potential of tumor cells. Mucins function through many unique domains that can form complex association with various signaling molecules including growth factor receptors and intercellular adhesion molecules. While there is growing information about mucins in various malignancies including breast cancer, no focused review is there on the expression and functional roles of mucins in breast cancer. In this present review, we have discussed the differential expression and functional roles of mucins in breast cancer. The potential of mucins as diagnostic and prognostic markers and as therapeutic targets in breast cancer have also been discussed.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277939      PMCID: PMC3230300          DOI: 10.1016/j.bbcan.2011.01.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  137 in total

1.  CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients.

Authors:  A D Cohen; J Gopas; G Karplus; Y Cohen
Journal:  Isr J Med Sci       Date:  1995 Feb-Mar

Review 2.  Mucin antibodies - new tools in diagnosis and therapy of cancer.

Authors:  U A Wittel; A Goel; G C Varshney; S K Batra
Journal:  Front Biosci       Date:  2001-10-01

3.  Mucin profiles in signet-ring cell carcinoma.

Authors:  Minh D Nguyen; Brian Plasil; Ping Wen; Wendy L Frankel
Journal:  Arch Pathol Lab Med       Date:  2006-06       Impact factor: 5.534

4.  miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death.

Authors:  Caining Jin; Hasan Rajabi; Donald Kufe
Journal:  Int J Oncol       Date:  2010-07       Impact factor: 5.650

5.  [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].

Authors:  Y Bensouda; F André; T Boulet; A Al-Ghuzlan; R Conforti; F Troalen; C Bourgier; H Errihani; M Spielmann; S Delaloge
Journal:  Bull Cancer       Date:  2009-10       Impact factor: 1.276

6.  Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies.

Authors:  Darius Dian; Wolfgang Janni; Christina Kuhn; Doris Mayr; Uwe Karsten; Ioannis Mylonas; Klaus Friese; Udo Jeschke
Journal:  Onkologie       Date:  2009-04-20

Review 7.  A new estrogen receptor antagonist--an overview of available data.

Authors:  Stephen E Jones
Journal:  Breast Cancer Res Treat       Date:  2002-10       Impact factor: 4.872

8.  MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1.

Authors:  Jennifer J Rahn; Qiang Shen; Brian K Mah; Judith C Hugh
Journal:  J Biol Chem       Date:  2004-05-28       Impact factor: 5.157

9.  Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.

Authors:  Magali Lacroix-Triki; Paula H Suarez; Alan MacKay; Maryou B Lambros; Rachael Natrajan; Kay Savage; Felipe C Geyer; Britta Weigelt; Alan Ashworth; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2010-11       Impact factor: 7.996

10.  Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1).

Authors:  Marina Isla Larrain; Sandra Demichelis; Marina Crespo; Ezequiel Lacunza; Alberto Barbera; Aldo Cretón; Francisco Terrier; Amada Segal-Eiras; María Virginia Croce
Journal:  J Exp Clin Cancer Res       Date:  2009-08-28
View more
  53 in total

Review 1.  Mucins and toll-like receptors: kith and kin in infection and cancer.

Authors:  Shikha Tarang; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2012-02-03       Impact factor: 8.679

Review 2.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

3.  Design of a specific colonic mucus marker using a human commensal bacterium cell surface domain.

Authors:  Yves-Marie Coïc; Francoise Baleux; Ömer Poyraz; Roman Thibeaux; Elisabeth Labruyere; Fabrice Chretien; Iradj Sobhani; Thierry Lazure; Benjamin Wyplosz; Gunter Schneider; Laurence Mulard; Philippe J Sansonetti; Benoit S Marteyn
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

Review 4.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

5.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

6.  Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.

Authors:  Anna Astashchanka; Thomas M Shroka; Britta M Jacobsen
Journal:  Breast Cancer Res Treat       Date:  2018-10-13       Impact factor: 4.872

7.  Differential diagnosis of otitis media with effusion using label-free Raman spectroscopy: A pilot study.

Authors:  Rishikesh Pandey; Chi Zhang; Jeon W Kang; Parind M Desai; Ramachandra R Dasari; Ishan Barman; Tulio A Valdez
Journal:  J Biophotonics       Date:  2018-01-17       Impact factor: 3.207

8.  Multipotent stem cells from trabecular meshwork become phagocytic TM cells.

Authors:  Yiqin Du; Danny S Roh; Mary M Mann; Martha L Funderburgh; James L Funderburgh; Joel S Schuman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-21       Impact factor: 4.799

9.  Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.

Authors:  Zéna Wimana; G Gebhart; T Guiot; B Vanderlinden; R Morandini; G Doumont; F Sherer; G Van Simaeys; S Goldman; G Ghanem; P Flamen
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

Review 10.  Review of the adenocarcinoma cell surface receptor for human alpha-fetoprotein; proposed identification of a widespread mucin as the tumor cell receptor.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.